11th May 2022 | Pharma Updates
Sun Pharma's Halol unit receives ten USFDA Form 483 observations
Sun Pharma claimed that USFDA issued a form 483 with ten observations during an examination of its Halol facility. However, the unit’s contribution to the company’s turnover is currently minimal.
Pfizer to invest $11.6 billion for Biohaven Pharmaceuticals
Pfizer Inc. has agreed to buy Biohaven Pharmaceutical Holding Co. for $11.6 billion in cash in order to secure approval for a migraine headache therapy.
Novavax 2022 COVID-19 vaccine deliveries are slow to begin
Novavax’s stock dropped nearly 16% after the firm announced a steep decline in first-quarter COVID-19 research funding and stated it shipped less than a fourth of the total vaccine deliveries anticipated for 2022.
Abbott introduces HBsAg Next Assay for the early identification of Hepatitis B
HBsAg Next Qualitative Assay from Abbott has been launched in India for early identification of the Hepatitis B virus for the prevention or delay of advanced liver disease progression, and also minimizes the chance of transmission.
CEPI collaborates with the Bharat Biotech Consortium to construct a 'variant-proof' COVID-19 vaccine
Bharat Biotech has collaborated with an international interdisciplinary collaboration and is scheduled to receive US $19.3 million in funding for the development of a ‘variant proof’ coronavirus vaccine candidate.
Emcure announces EmWocal, a public awareness campaign
Emcure Pharmaceuticals has created the EmWocal project to raise awareness of essential women’s health issues such as anaemia, breastfeeding, and menstruation.
BioNTech extended COVID-19 vaccine study in China until October
A Phase II clinical trial of BioNTech’s COVID-19 vaccine in China has been extended by six months, through October, according to a register of such trials.
